Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses (Q46827654)

25 December 2017

title

Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses (English)

1 reference

25 December 2017

author name string

Yongxin Zhang

1

1 reference

25 December 2017

Jianxia Qiu

2

1 reference

25 December 2017

Yu Zhou

3

1 reference

25 December 2017

Farhang Farhangfar

4

1 reference

25 December 2017

Jenny Hester

5

1 reference

25 December 2017

Augustine Y Lin

6

1 reference

25 December 2017

William K Decker

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

18 December 2007

1 reference

25 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

25 December 2017

volume

26

1 reference

25 December 2017

issue

5

1 reference

25 December 2017

page(s)

614-622

1 reference

25 December 2017

Inhalational anthrax: epidemiology, diagnosis, and management

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Molecular pathogenesis of Bacillus anthracis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Anthrax vaccine. Model of a response to the biologic warfare threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

The effectiveness and safety of vaccines against human anthrax: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

The Sverdlovsk anthrax outbreak of 1979

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Presentation of protective antigen to the mouse immune system: immune sequelae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Development of novel vaccines against anthrax in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Bacillus anthracis surface: capsule and S-layer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell-associated antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

The capsule of bacillus anthracis, a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Delivery of antigens to the MHC class I pathway using bacterial toxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Anthrax toxin fusion proteins for intracellular delivery of macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Genetic immunization against anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.072

10.1016/J.VACCINE.2007.11.072

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017